-positive individuals in the NA-na e group; nevertheless, the difference was more pronounced in HBeAgpositive individuals (7.98 versus 7.32, P 0.001). Response to TDF therapy. The imply duration of remedy with TDF was 29 (range, six to 52) months, and also the durations have been comparable within the two groups (Table 1). In the sufferers with LAM-F, 71 (77 ) had been treated with a combination of lamivudine and TDF and 21 (23 ) sufferers have been treated with TDF monotherapy. The proportion of HBeAg-negative patients having a CVR during the follow-up was 85 (55/65) within the NA-na e group and 91 (61/ 67) within the LAM-F group (P 0.26). The CVR rate in HBeAgpositive individuals was also related within the NA-na e group and the LAM-F group (60 [24/40] versus 64 [16/25], P 0.75). TheApril 2013 Volume 57 Numberaac.asm.orgBaran et al.TABLE 1 Baseline demographic, clinical, and laboratory characteristics of your individuals within this studyCharacteristic No. ( ) of sufferers Mean age (yr) SD No. ( ) of: Males Females No. ( ) with cirrhosis Child-Pugh class A Child-Pugh class B Child-Pugh class C Baseline ALT level (IU/liter) Mean SD Median (range) No. ( ) with baseline ALT level above ULN No. ( ) with HBeAg status of: Damaging Constructive Baseline HBV DNA level (log10 IU/ml) Mean SD Median (variety) No. ( ) with genotypic resistance Median liver histology (range) Ishak stage HAI No. ( ) treated with: TDF monotherapy Lamivudine-TDF combination Treatment duration (mo) Imply SD Median (range)aOverall 197 (100) 43NA na e 105 (53) 40LAM-F 92 (47) 45P value 0.136 (69) 61 (31) 45 (23) 32 (71) 11 (24) two (4)73 (70) 32 (30) 15 (14) 13 (87) 2 (13) 0 (0)63 (68) 29 (32) 30 (33) 19 (63) 9 (30) two (7)0.0.002 0.05a 0.05a 0.05a98 120 56 (9?06) 119 (60)119 123 77 (19?06) 82 (78)74 113 40 (9?81) 37 (40)0.001 0.132 (67) 65 (33)65 (62) 40 (38)67 (73) 25 (27)0.7.48 8.02 six.46 (1.73?.13) 74 (38)7.66 8.14 7.12 (2.09?.13)7.11 7.49 five.42 (1.73?.14) 74 (80)0.two (2?) six (five?5)2 (two?) 7 (five?four)2 (two?) six (six?5)0.19 0.126 (64) 71 (36)105 (one hundred) 0 (0)21 (23) 71 (77)0.7-Bromochromane-3-carboxylic acid uses 28 14 29 (six?2)28 14 28 (six?two)29 14 30 (six?1)0parison of column proportions,test with Bonferroni adjustment.Formula of 1,2,4-Triazolidine-3,5-dione cumulative CVR prices of HBeAg-negative individuals in the NA-na e and LAM-F groups had been 52 versus 67 at six months, 82 versus 81 at 12 months, 88 versus 93 at 24 months, and 94 versus 96 at 36 months, respectively (Fig.PMID:33480323 1a; log-rank test, P 0.ten). The cumulative CVR prices within the NA-na e and LAM-FTABLE 2 Baseline polymerase sequence mutations in 74 sufferers with LAM-FCharacteristic Resistance mutations rtL80I/V rtV173L rtL180M rtA181T rtM204I/V Most typical combinations of resistance mutations rtL80I/V, rtL180M, and rtM204I/V rtL180M and rtM204I/V rtL80I/V and rtM204I/V No. ( ) of patients 42 (56.7) 5 (six.7) 49 (66) 1 (1.three) 69 (93)24 (32) 22 (30) 15 (20)groups of HBeAg-positive sufferers were 15 versus 12 at six months, 39 versus 43 at 12 months, 61 versus 74 at 24 months, and 67 versus 83 at 36 months, respectively (Fig. 1b; log-rank test, P 0.48). Regardless of a greater baseline HBV DNA level within the NA-na e group, HBV DNA suppression curves throughout TDF therapy were related in the two groups, particularly just after six months of therapy (Fig. 2). The times to a CVR had been comparable within the monotherapy and add-on mixture therapy arms of individuals with LAM-F (89 versus 88 at 24 months; log-rank test, P 0.23). Univariate Cox regression analyses from the total group revealed that age in the initiation of TDF therapy (HR, 1.016; 95 CI, 1.002 to 1.030; P 0.02), HBeAg positivity (HR, 0.35; 9.